Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs Conbercept Effects on FVMs in PDR
NCT07144865Completed
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of faricimab in proliferative diabetic retinopathy (PDR) (3 arms). Primary endpoints: Concentration of Anti-VEGF Agents on Angiogenic Factors in FVMs, Concentration of Anti-VEGF Therapy on Myofibroblast Products and Profibrotic Factors in FVMs and 1 more. Started Dec 2024; status: completed.
02
Drugs
faricimab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT07144865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144865.